Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group-Reference-Cited by-同舟云学术

Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group

Published:2021-12-16 Issue:1 Volume:24 Page:57-62
ISSN:1174-5878
Container-title:Pediatric Drugs
language:en
Short-container-title:Pediatr Drugs

Author:

Dipasquale Valeria,Martinelli Massimo,Aloi Marina,Accomando Salvatore,Alvisi Patrizia,Arrigo Serena,Banzato Claudia,Bramuzzo Matteo,Cananzi Mara,Corpino Mara,Di Mari Clelia,Di Nardo Giovanni,Dilillo Anna,Dodaro Natale,Felici Enrico,Gatti Simona,Graziano Francesco,Illiceto Maria Teresa,Norsa Lorenzo,Opramolla Anna,Pastore Maria,Pavanello Paolo Maria,Romeo Erminia,Scarallo Luca,Strisciuglio Caterina,Zuin Giovanna,Romano Claudio

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pediatrics, Perinatology and Child Health

Link

https://link.springer.com/content/pdf/10.1007/s40272-021-00486-8.pdf

Reference14 articles.

1. Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn’s and Colitis Organization. J Crohns Colitis. 2014;8:1548–50.

2. Danese S, Fiorino G, Michetti P. Changes in biosimilar knowledge among European Crohn’s Colitis Organization [ECCO] Members: an updated survey. J Crohns Colitis. 2016;10:1362–5.

3. de Ridder L, Assa A, Bronsky J, et al. Use of biosimilars in pediatric inflammatory bowel disease: an updated position statement of the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2019;68:144–53.

4. Dipasquale V, Romano C. Biosimilar infliximab in paediatric inflammatory bowel disease: Efficacy, immunogenicity and safety. J Clin Pharm Ther. 2020;45:1228–34.

5. Park SK, Moon W, Kim ES, et al. Knowledge and viewpoints on biosimilar monoclonal antibodies among Asian physicians: comparison with European physicians. Korean J Gastroenterol. 2019;74:333–40.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience;Expert Opinion on Biological Therapy;2024-07-02

2. Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review;Pediatric Drugs;2023-06-15

3. Biosimilars in Pediatric IBD: Updated Considerations for Disease Management;Biologics: Targets and Therapy;2022-06